Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.59 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.59 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.59 |
| ▸ | PRCP | P42785 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8104014 | 0.90 | DRD2 (0.68) | DRD2SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL11932493 | 0.87 | SIGMAR1 (0.45) | DRD2SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL9967721 | 0.85 | PRCP (0.48) | DRD2SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL9967731 | 0.85 | DRD2 (0.68) | DRD2MEN1KMT2APRCP | |
| SCHEMBL9967718 | 0.85 | DRD2 (0.55) | DRD2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7259165 | 0.83 | SIGMAR1 (0.75) | DRD2SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL29110823 | 0.83 | SLC18A3 (0.66) | DRD2SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL11932474 | 0.82 | DRD2 (0.68) | DRD2SIGMAR1CYP3A4 | |
| SCHEMBL152587 | 0.82 | DRD2 (0.81) | DRD2SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL9967719 | 0.81 | HRH3 (0.53) | DRD2SIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20070197546-A1 | QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM SPA, ITALY | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | DHPS, FDPS, DPYD | DRD2 1749/4885SIGMAR1 1773/4885MEN1 3414/4885 |
| US-20070197546-A1 | QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | KCNH2, KCNH3, KCNJ2 | DRD2 176/4885SIGMAR1 350/4885MEN1 1638/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | DRD2 1749/4885SIGMAR1 1773/4885MEN1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.